Having trouble accessing articles? Reset your cache.

Mammoth eyes CRISPR-based therapeutics with new funding

CRISPR company Mammoth looks beyond diagnostics with Decheng Capital-led $45M series B

With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its IP position around an alternative CRISPR enzyme and expanding its gene editing capabilities beyond diagnostics into a range of therapeutic applications.

Mayfield, NFX, Verily and Brook Byers also participated in the round, which brings the company’s total funding to over $70 million to date.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE